ESMO 2026 Highlights – Part 2

Episode
399
Soundcloud
Share

In Part 2 of our ESMO 2026 Highlights series, Dr. Stephen Liu and Dr. Narjust Florez welcome Dr. Xiao-Rong Dong, Dr. Yi-Long Wu, and Dr. Chantal Decroisette to discuss three important clinical trials: SAFFRON, SANOVO, and PERSEE. The conversations explore emerging strategies for targeting MET in EGFR-mutated non-small cell lung cancer, advances in first-line immunotherapy, and the potential implications of these findings for clinical practice.

Guest
Stephen Liu
Stephen Liu

MD

Chief of Hematology and Oncology
Georgetown University
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Chantal Decroisette
Chantal Decroisette

MD

Thoracic Oncologist, Medical Oncology Department
Centre Léon Bérard, Lyon
Xiao-Rong Dong
Xiao-Rong Dong

MD, PhD

Professor, Chief Physician and Doctoral Supervisor
Director, Department of Thoracic Oncology
Cancer Center of Union Hospital, Huazhong University of Science and Technology
Yi-Long Wu
Yi-Long Wu

MD

Professor, Guangdong Lung Cancer Institute
Guangdong Provincial People’s Hospital